161 related articles for article (PubMed ID: 38365379)
1. Comparative effectiveness of azathioprine and mycophenolate mofetil for myasthenia gravis (PROMISE-MG): a prospective cohort study.
Narayanaswami P; Sanders DB; Thomas L; Thibault D; Blevins J; Desai R; Krueger A; Bibeau K; Liu B; Guptill JT;
Lancet Neurol; 2024 Mar; 23(3):267-276. PubMed ID: 38365379
[TBL] [Abstract][Full Text] [Related]
2. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis.
Sanders DB; Hart IK; Mantegazza R; Shukla SS; Siddiqi ZA; De Baets MH; Melms A; Nicolle MW; Solomons N; Richman DP
Neurology; 2008 Aug; 71(6):400-6. PubMed ID: 18434638
[TBL] [Abstract][Full Text] [Related]
3. Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study.
Granit V; Benatar M; Kurtoglu M; Miljković MD; Chahin N; Sahagian G; Feinberg MH; Slansky A; Vu T; Jewell CM; Singer MS; Kalayoglu MV; Howard JF; Mozaffar T;
Lancet Neurol; 2023 Jul; 22(7):578-590. PubMed ID: 37353278
[TBL] [Abstract][Full Text] [Related]
4. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
[TBL] [Abstract][Full Text] [Related]
5. Immunosuppressive agents for myasthenia gravis.
Hart IK; Sathasivam S; Sharshar T
Cochrane Database Syst Rev; 2007 Oct; (4):CD005224. PubMed ID: 17943844
[TBL] [Abstract][Full Text] [Related]
6. Mycophenolate mofetil in the therapy of severe myasthenia gravis.
Schneider C; Gold R; Reiners K; Toyka KV
Eur Neurol; 2001; 46(2):79-82. PubMed ID: 11528156
[TBL] [Abstract][Full Text] [Related]
7. Non-biologic, steroid-sparing therapies for non-infectious intermediate, posterior, and panuveitis in adults.
Edwards Mayhew RG; Li T; McCann P; Leslie L; Strong Caldwell A; Palestine AG
Cochrane Database Syst Rev; 2022 Oct; 10(10):CD014831. PubMed ID: 36315029
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study.
Bril V; Drużdż A; Grosskreutz J; Habib AA; Mantegazza R; Sacconi S; Utsugisawa K; Vissing J; Vu T; Boehnlein M; Bozorg A; Gayfieva M; Greve B; Woltering F; Kaminski HJ;
Lancet Neurol; 2023 May; 22(5):383-394. PubMed ID: 37059507
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
Howard JF; Utsugisawa K; Benatar M; Murai H; Barohn RJ; Illa I; Jacob S; Vissing J; Burns TM; Kissel JT; Muppidi S; Nowak RJ; O'Brien F; Wang JJ; Mantegazza R;
Lancet Neurol; 2017 Dec; 16(12):976-986. PubMed ID: 29066163
[TBL] [Abstract][Full Text] [Related]
10. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis.
Dooley MA; Jayne D; Ginzler EM; Isenberg D; Olsen NJ; Wofsy D; Eitner F; Appel GB; Contreras G; Lisk L; Solomons N;
N Engl J Med; 2011 Nov; 365(20):1886-95. PubMed ID: 22087680
[TBL] [Abstract][Full Text] [Related]
11. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid.
Beissert S; Werfel T; Frieling U; Böhm M; Sticherling M; Stadler R; Zillikens D; Rzany B; Hunzelmann N; Meurer M; Gollnick H; Ruzicka T; Pillekamp H; Junghans V; Bonsmann G; Luger TA
Arch Dermatol; 2007 Dec; 143(12):1536-42. PubMed ID: 18087004
[TBL] [Abstract][Full Text] [Related]
12. Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability.
Meriggioli MN; Ciafaloni E; Al-Hayk KA; Rowin J; Tucker-Lipscomb B; Massey JM; Sanders DB
Neurology; 2003 Nov; 61(10):1438-40. PubMed ID: 14638974
[TBL] [Abstract][Full Text] [Related]
13. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
Loncharich MF; Anderson CW
ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
[TBL] [Abstract][Full Text] [Related]
14. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
15. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.
Howard JF; Bril V; Vu T; Karam C; Peric S; Margania T; Murai H; Bilinska M; Shakarishvili R; Smilowski M; Guglietta A; Ulrichts P; Vangeneugden T; Utsugisawa K; Verschuuren J; Mantegazza R;
Lancet Neurol; 2021 Jul; 20(7):526-536. PubMed ID: 34146511
[TBL] [Abstract][Full Text] [Related]
16. Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial.
Wolfe GI; Kaminski HJ; Aban IB; Minisman G; Kuo HC; Marx A; Ströbel P; Mazia C; Oger J; Cea JG; Heckmann JM; Evoli A; Nix W; Ciafaloni E; Antonini G; Witoonpanich R; King JO; Beydoun SR; Chalk CH; Barboi AC; Amato AA; Shaibani AI; Katirji B; Lecky BRF; Buckley C; Vincent A; Dias-Tosta E; Yoshikawa H; Waddington-Cruz M; Pulley MT; Rivner MH; Kostera-Pruszczyk A; Pascuzzi RM; Jackson CE; Verschuuren JJGM; Massey JM; Kissel JT; Werneck LC; Benatar M; Barohn RJ; Tandan R; Mozaffar T; Silvestri NJ; Conwit R; Sonett JR; Jaretzki A; Newsom-Davis J; Cutter GR;
Lancet Neurol; 2019 Mar; 18(3):259-268. PubMed ID: 30692052
[TBL] [Abstract][Full Text] [Related]
17. Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial.
Remuzzi G; Lesti M; Gotti E; Ganeva M; Dimitrov BD; Ene-Iordache B; Gherardi G; Donati D; Salvadori M; Sandrini S; Valente U; Segoloni G; Mourad G; Federico S; Rigotti P; Sparacino V; Bosmans JL; Perico N; Ruggenenti P
Lancet; 2004 Aug 7-13; 364(9433):503-12. PubMed ID: 15302193
[TBL] [Abstract][Full Text] [Related]
18. Depressive disorder associated with mycophenolate mofetil.
Draper HM
Pharmacotherapy; 2008 Jan; 28(1):136-9. PubMed ID: 18154484
[TBL] [Abstract][Full Text] [Related]
19. Can mycophenolate mofetil be tapered safely in myasthenia gravis? A retrospective, multicenter analysis.
Hobson-Webb LD; Hehir M; Crum B; Visser A; Sanders D; Burns TM
Muscle Nerve; 2015 Aug; 52(2):211-5. PubMed ID: 25906756
[TBL] [Abstract][Full Text] [Related]
20. Survival Associated With Sirolimus Plus Tacrolimus Maintenance Without Induction Therapy Compared With Standard Immunosuppression After Lung Transplant.
Wijesinha M; Hirshon JM; Terrin M; Magder L; Brown C; Stafford K; Iacono A
JAMA Netw Open; 2019 Aug; 2(8):e1910297. PubMed ID: 31461151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
